Abstract:Introduction: Wilms tumor (WT) is the most common pediatric renal malignancy. Current guidelines that stratify WT risk and determine treatment courses are inadequate, as over 60 % of WT survivors develop treatment-related complications. Recently, numerous advances in establishing patient sub-groups with different clinical features have been realized by evaluating the adaptive immune receptor (IR) complementarity determining region-3 (CDR3) amino acid (AA) sequences, a reasonable series of successes, given the prominent role of the CDR3 in antigen binding, including tumor antigen binding. However, the possibility that adaptive IR chemical variability correlates with distinct survival outcomes for WT has not yet been explored. Objective: The goal of this study was to isolate the T-cell receptor and B-cell receptor recombination, sequencing reads from WT RNAseq files, representing the actual tumor tissue, translate the sequences to AAs, identify the adaptive IR CDR3 domains, and determine whether the physicochemical properties of those CDR3 AA sequences correlated with survival probability distinctions. Study design: WT RNA-seq files were mined to obtain the CDR3 AAs for various adaptive IRs. The physicochemical properties of these CDR3s were examined for trends in how those properties correlated with survival probabilities for WT patients, using a Kaplan-Meier analyses, verified via several approaches. Results: The above processes indicated the association of the (a) IGL CDR3s' instability index and the (b) TRG CDR3s' fraction disorder promoting features with better outcomes. Additionally, the IGL CDR3 data were assessed using the Predictor of Natural Disordered Regions web tool, which strengthened the evidence for the association with the IGL CDR3 instability index with a better outcome. Discussion: The approaches described here indicate that greater adaptive IR CDR3 instability and flexibility may serve as prognostic indicators; and may indicate the flexibility of CDR3 domains provides for greater opportunity to bind tumor antigens. Conclusion: Further exploration and development of these approaches and findings may lead to new guidelines for more precise treatment regimens, or even watchful waiting periods, that could thereby decrease the lifetime occurrence of adverse events.

Modeling high-risk Wilms tumors enables the discovery of therapeutic vulnerability

Investigating the Dysfunctional Pathogenesis of Wilms' Tumor Through a Multidimensional Integration Strategy.

Forty-five Patient-Derived Xenografts Capture the Clinical and Biological Heterogeneity of Wilms Tumor

The development of Wilms tumor: from WT1 and microRNA to animal models.

The synergistic effects of anoikis-related genes and EMT-related genes in the prognostic prediction of Wilms tumor

Wilms’ Tumor Primary Cells Display Potent Immunoregulatory Properties on NK Cells and Macrophages

Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin

Delineating the Interplay Between Oncogenic Pathways and Immunity in Anaplastic Wilms Tumors.

Discovery of Novel Potential Prognostic Markers and Targeted Therapy to Overcome Chemotherapy Resistance in an Advanced-Stage Wilms Tumor

Bioinformatical Analysis of the Key Differentially Expressed Genes for Screening Potential Biomarkers in Wilms Tumor.

Immune-related gene signature associates with immune landscape and predicts prognosis accurately in patients with Wilms tumour

Rna-Sequencing, Connectivity Mapping, And Molecular Docking To Investigate Ligand-Protein Binding For Potential Drug Candidates For The Treatment Of Wilms Tumor

Identification of a 12-Gene Signature and Hub Genes Involved in Kidney Wilms Tumor Via Integrated Bioinformatics Analysis

Targeting the HIF-1α-IGFBP2 axis therapeutically reduces IGF1-AKT signaling and blocks the growth and metastasis of relapsed anaplastic Wilms tumor

Stratification of Wilms tumor patients using physicochemical properties of the adaptive immune receptor polypeptides, IGL and TRG

Screening of potential hub genes involved in Kidney Wilms tumor via bioinformatics analysis and experimental validation

Abstract 1103: Molecular signature for treatment-responsive and recurrent Wilms tumors

New approaches to risk stratification for Wilms tumor

Identification of key carcinogenic genes in Wilms' tumor

Pharmacologic Inhibition of β-Catenin With Pyrvinium Inhibits Murine and Human Models of Wilms Tumor

ZMIZ1 Affects Invasion and Metastasis of Wilms Tumor by Regulating Notch Signaling Pathway